FORWARDHEALTH PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR PROTON PUMP INHIBITOR (PPI) ORALLY DISINTEGRATING TABLETS

Instructions: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Proton Pump Inhibitor (PPI) Orally Disintegrating Tablets Completion Instructions, F-00433A. Providers may refer to the Forms page of the ForwardHealth Portal at *www.forwardhealth.wi.gov/WIPortal/subsystem/publications/forwardhealth.communications.aspx?* panel=Forms for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Preferred Drug List (PA/PDL) for Proton Pump Inhibitor (PPI) Orally Disintegrating Tablets form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal, by fax, or by mail. Providers may call Provider Services at 800-947-9627 with questions.

SECTION I — MEMBER INFORMATION

1. Name — Member (Last, First, Middle Initial)

2. Member Identification Number	3. Date of Birth — Member					
SECTION II — PRESCRIPTION INFORMATION						
4. Drug Name	5. Drug Strength					
6. Date Prescription Written	7. Refills					
8. Directions for Use						
9. Name — Prescriber	10. National Provider Identifier (NPI) — Prescriber					
11. Address — Prescriber (Street, City, State, ZIP+4 Code)						
12. Telephone Number — Prescriber						
SECTION III — CLINICAL INFORMATION (Required for all PA requests.)						
13. Diagnosis Code and Description						

14.	14. Has the member experienced an unsatisfactory therapeutic response or a clinically significant adverse drug reaction with any dosage form of esomeprazole?		Yes	No
	If yes, list the dates esomeprazole was taken.		_	

Describe the unsatisfactory therapeutic response or clinically significant adverse drug reaction.

Continued



DT-PA040-040

SECTION III — CLINICAL INFORMATION (Required for all PA requests.) (Continued)		
15. Is there a clinically significant drug interaction between another drug the member is taking and esomeprazole?	Yes	No
If yes, list the drug(s) and interaction(s) in the space provided.		
16. Has the member experienced an unsatisfactory therapeutic response or a clinically significant adverse drug reaction with any dosage form of omeprazole?	Yes	No
If yes, list the dates omeprazole was taken.		
Describe the unsatisfactory therapeutic response or clinically significant adverse drug reaction.		
17. Is there a clinically significant drug interaction between another drug the member is taking and omeprazole?	Yes	No
If yes, list the drug(s) and interaction(s) in the space provided.		
18. Has the member experienced an unsatisfactory therapeutic response or a clinically significant adverse drug reaction with any dosage form of pantoprazole? (If the member is under 5 years old, check "N/A.")	No	N/A
If yes, list the dates pantoprazole was taken.		
Describe the unsatisfactory therapeutic response or clinically significant adverse drug reaction.		
19. Is there a clinically significant drug interaction between another drug the member is taking and pantoprazole? (If the member is under 5 years old, check "N/A.")	No	N/A
If yes, list the drug(s) and interaction(s) in the space provided.		

SECTION III - CLINICAL INFORMATION	(Required for all PA required for all PA requi	uests.) (Continued	l)				
20. Does the member have a medical cond	lition(s) that prevents the u	se of			1		
PPI suspensions?				Yes		No	
If yes, list the medical condition(s) and space provided.	describe how the condition	(s) prevents the me	ember from using PF	PI suspens	ions i	n the	
21. Is member preference the reason why	the member is unable to ta	ke PPI suspensions	s? 🛛	Yes		No	
SECTION IV — AUTHORIZED SIGNATUR	RE						
22. SIGNATURE — Prescriber		23. Date Signed					
SECTION V — FOR PHARMACY PROVID	DERS USING STAT-PA						
24. National Drug Code (11 Digits)	25. Days' Supply Requested (Up to 365 Days)						
26. NPI							
27. Date of Service (MM/DD/CCYY) (For S days in the past.)	TAT-PA requests, the date	of service may be	up to 31 days in the	future and	d / or	up to 14	
28. Place of Service							
29. Assigned PA Number							
30. Grant Date	31. Expiration Date		32. Number of Da	ys Approv	ed		
SECTION VI — ADDITIONAL INFORMAT	ION		1				
33. Include any additional information in the	e space below. Additional c	liagnostic and clinic	al information expla	ining the r	need f	or the	

drug requested may be included here.